Barrett Lawson, MD
Department of Anatomical Pathology, Division of Pathology-Lab Medicine Div
About Dr. Barrett Lawson
I’m an anatomic and clinical pathologist with training in gynecologic-oncologic pathology. I have a special interest in ovarian tumors, tumor biomarkers and therapy response. I routinely review difficult and challenging gynecologic pathology cases not only from surgical specimens here at MD Anderson but also from cases sent from the outside for referral and consultation. In addition to my diagnostic responsibilities, I work on multiple research projects in collaboration with colleagues in gynecologic oncology. I also work closely with our pathology fellows in educational endeavors, including routine multi-head scope review and teaching of cases.
Present Title & Affiliation
Primary Appointment
Associate Professor, Pathology, University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Voluntary Clinical Associate Professor, Department of Clinical Services, University of Houston Tilman J. Fertitta Family College of Medicine, Houston, Texas
Associate Professor, Pathology, University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2014 | Texas A&M Health Science Center, College Station, Texas, US, MD |
| 2010 | Abilene Christian University, Abilene, Texas, US, Biology, BS |
Postgraduate Training
| 2018-2019 | Clinical Fellowship, Gynecological Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2018 | Clinical Residency, Anatomic and Clinical Pathology, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2018 | American Board of Pathology, Anatomical and Clinical Pathology, Lifetime |
| 2017 | Texas Medical Board |
Experience & Service
Administrative Appointments/Responsibilities
Associate Director of Institutional Tissue Bank, Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2026 - Present
Medical Director of Frozen Section Laboratory, Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Institutional tissue Bank Clinical Co-Director, Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2023
Intramural Institutional Committee Activities
Committee Member, GSBS Masters Advisory Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2021
Extramural Institutional Committee Activities
Member, Digital Pathology Stakeholder Group, The University of Texas MD Anderson Cancer Center, 2025 - Present
Special Task Force for Extended Hours, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2024 - 2024
Member, OR Capacity Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, AP Capacity Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, GYN-ONC CCSG Planning Committee, The University of Texas MD Anderson Cancer Center, 2023
Thesis Committee Member, Thesis Proposal - Gabriela Rincon, The University of Texas MD Anderson Cancer Center, 2023 - Present
Voting member, ITB Advisory Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Chair, Frozen Section Advisory Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Voting Member, OR Advisory Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Russell Conference Planning Committee, The University of Texas MD Anderson Cancer Center, 2023
Member/Reviewer, Protocol Assessment and Review Committee (PARC) for Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 2021 - Present
Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2021 - 2024
Chair, ITB Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Member, Gynecologic Pathology Fellowship CCC/PEC, The University of Texas MD Anderson Cancer Center, 2019 - Present
Honors & Awards
| 2025 - Present | MD Anderson's Celebration of Faculty Excellence: Quality Improvement and Patient Safety, The University of Texas MD Anderson Cancer Center |
| 2024 | Shirley Stein Scientific Endowment Award, MD Anderson Cancer Center: Anatomic Pathology |
| 2023 | Division Head: Faculty Educator Award, MD Anderson Cancer Center: Division of Pathology and Laboratory Medicine |
| 2022 - Present | Division of Pathology and Laboratory Medicine - Early Career Research Grant |
| 2022 | Oncologic Pathology Teaching Award, MD Anderson Cancer Center: Anatomic Pathology |
| 2021 | Oncologic Pathology Teaching Award, MD Anderson Cancer Center: Anatomic Pathology |
| 2016 - 2017 | Medical Education and Teaching Award for Outstanding Teaching, Baylor College of Medicine |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Gynecologic Pathology Case Presentation. Invited. Russell Pathology Conference. Houston, Texas, US.
- 2024. Overview of Gynecologic Pathology: GYN Oncology Research Series. Invited. GYN Oncology Research Series. Houston, Texas, US.
- 2024. Endometrial Cancer Biomarkers. Invited. Houston, Texas, US.
- 2020. Gynecologic Pathology Soundbites. Conference. MD Anderson, US.
- 2017. Quality Improvement in Transfusion Reaction Hand-Off and Reporting at Texas Children’s Hospital. Conference. Baylor College of Medicine, US.
Regional Presentations
- 2025. To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer. USCAP. Boston, Massachusetts, US.
National Presentations
- 2026. Ovarian Mucinous Tumors: Avoid Getting Stuck in the Muc. Conference. College of American Pathologist. Las Vegas, Nevada, US.
- 2026. Powering Pathology Precision: Expert Strategies for Folate Receptor Alpha Testing to Guide Personalized ADC Care in Advanced Ovarian Cancer. OnlineOnly.
- 2026. Etiology, Clinical Presentation, Diagnosis and Staging of Ovarian Cancer. Invited. ASCO Advantage. Houston, TX.
- 2026. Etiology, Pathogenesis and Clinical Presentation of Endometrial Cancer. Invited. ASCO Advantage. Houston, TX.
- 2026. Testing, Diagnosis and Staging of Endometrial Cancer. Invited. ASCO Advantage. Houston, Texas.
- 2026. Ovarian Cancer: Antibody Drug Conjugates. Florida Society of Pathologists. Manalapan, Florida.
- 2026. Ovarian Cancer: Antibody Drug Conjugates. New York Society of Pathology. Uniondale, New York, US.
- 2026. Ovarian Cancer: Antibody Drug Conjugates. Conference. New Jersey Society of Pathologists. New Brunswick, New Jersey, US.
- 2026. Ovarian Cancer: Antibody Drug Conjugates. Conference. Maryland and DC Society of Pathologists. Bethesda, MD, US.
- 2025. Platinum Resistant Ovarian Cancer. OnlineOnly. Medlive, US.
- 2024. Lecture: Endocervical adenocarcinoma, HPV associated and unassociated lesions. Conference. College of American Pathologist. Las Vegas, Nevada, US.
- 2024. MDT in Endometrial Cancer. OnlineOnly, US.
- 2023. Lecture: Endocervical adenocarcinoma, HPV associated and unassociated lesions. Conference. Annual College of American Pathologists Meeting. Chicago, IL, US.
- 2023. Slide Microscopy Endocervical adenocarcinoma, HPV associated and unassociated lesions. Conference. Annual College of American Pathologists Meeting. Chicago, IL, US.
- 2019. High Grade Serous Carcinoma and Risk Reducing Salpingo-Oophorectomy: A Practical Review. Invited. Medical College of Wisconsin. Milwaukee, WI, US.
- 2019. Squamous and Glandular Lesions of the Vulva and Cervix. Invited. Medical College of Wisconsin. Milwaukee, WI, US.
- 2019. A Three-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High Grade Serous Carcinoma, Is It Clinically Relevant?. Invited. USCAP Gynecologic Pathology Platform. National Harbor, MD, US.
- 2017. Intraoperative Consultation in Low Grade Endometrial Endometrioid Adenocarcinoma: Is Frozen Section Superior to Gross Examination?. Invited. USCAP Gynecologic Pathology Platform Session. Seattle, WA, US.
International Presentations
- 2025. Review of Endometrial Carcinoma Through the Lense of TCGA and 2023 FIGO Staging. Invited. SEAP Spanish Pathologist Society. San Sebastian, ES.
- 2025. Biomarkers in Ovarian Tumors. Invited. SEAP Spanish Pathologist Society. San Sebastian, ES.
- 2024. Clinical Behavior and Gene Expression in Borderline and Malignant Brenner Tumors - Platform presentation. Poster. European Congress of Pathology. Florence, IT.
Grant & Contract Support
| Date: | 2024 - 2029 |
| Title: | A 3D endometrial pre-cancer atlas with spatially-resolved cellular and molecular profiling |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00021077 |
| Date: | 2024 - 2025 |
| Title: | Transposable elements as an opportunity to intercept BRCA1/2- mutant ovarian cancer |
| Funding Source: | Basser Center for BRCA |
| Role: | Other Significant Contributor |
| ID: | FP00021969 |
| Date: | 2024 - 2029 |
| Title: | 3D Spatial Multi-Omics Profiling of Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00021171 |
| Date: | 2024 - 2025 |
| Title: | Oncoexaptation as an Opportunity to Detect and Intercept Early Ovarian HGSC |
| Funding Source: | PhRMA Foundation |
| Role: | Collaborator |
| ID: | FP00021816 |
| Date: | 2024 - 2027 |
| Title: | Cancer associated fibroblasts and TGFbeta inhibitor response in ovarian granulosa cell tumors |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP240204 |
| Date: | 2023 - 2024 |
| Title: | Leveraging Non-Coding Genomic Regions for Early HGSC Detection |
| Funding Source: | Minnesota Ovarian Cancer Alliance |
| Role: | Other Significant Contributor |
| ID: | FP00020468 |
| Date: | 2023 - 2028 |
| Title: | Novel orally bioavailable imipridone ONC206 in advanced uterine cancer treatment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00018331 |
| Date: | 2023 - 2024 |
| Title: | Role of the pro-inflammatory omental microenvironment in ovarian cancer progression |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R37CA261952-01A1 |
| Date: | 2023 - 2024 |
| Title: | Targeting Ovarian Cancer Minimal Residual Disease (MRD) Using Immune and DNA Repair Directed Therapies |
| Funding Source: | Break Through Cancer |
| Role: | Co-I |
| ID: | FP0015195_Con1 |
| Date: | 2023 - 2024 |
| Title: | Understanding and Intercepting Ovarian Carcinogenesis (MOD) |
| Funding Source: | Breakthrough Cancer (BTC) |
| Role: | Collaborator |
| ID: | FP00015204_Con1 |
| Date: | 2019 - 2020 |
| Title: | MD Anderson Gynecologic SPORE for Uterine Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5P50CA098258-14 |
| Date: | 2016 - 2023 |
| Title: | MD Anderson Gynecologic SPORE for Uterine Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5P50CA098258-15 |
Selected Publications
Peer-Reviewed Articles
- Lawson BC, Malpica A. Folate Receptor Immunohistochemical Staining Heterogeneity in Gynecologic Cancers. Int J Gynecol Pathol, 2026. e-Pub 2026. PMID: 42550590.
- Mohamed KS, Ramalingam P, Lawson BC, Euscher ED, Sun CC, Malpica A. HER2 Immunohistochemical Expression and Fluorescent In Situ Hybridization (FISH) Testing in Clear Cell Carcinoma of the Gynecologic Tract. Appl Immunohistochem Mol Morphol, 2026. e-Pub 2026. PMID: 42474091.
- Cobb LP, Dai Y, Molina Ayala M, Ozirmak Lermi N, Hernandez SD, Davis J, Lee S, Lawson BC, Hajek RA, Celestino J, Liu J, Wang L, Soto LMS, Haymaker C, Chen K, Jiang M, Lu W, Sanchez-Espiridion B, Dang M, Hull S, Vining D, Fellman B, Yuan Y, Sood AK, Westin SN, Taylor J, Bevers M, Shafer A, Fleming ND, Lu KH, Gershenson DM, Jazaeri AA. A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma. Nat Commun 17(1), 2026. e-Pub 2026. PMID: 42374029.
- Marques-Piubelli ML, Lima CFP, Lawson BC, Pandurengan R, Batra S, Duenas DE, Parra ER, Rodriguez S, Wistuba II, Ramalingam P, Malpica A, Euscher ED. Extrauterine mesonephric-like carcinoma: a tumor with a cold lymphocytic immune microenvironment. Virchows Arch, 2026. e-Pub 2026. PMID: 42159715.
- Yu K, Tidwell RS, Bathala TK, Sheth RA, Karki M, Chen J, Qian J, Duan F, Perelli L, Soeung M, Rao P, Siefker-Radtke AO, Daw NC, Ingram DR, Shamsutdinova D, Wani KM, Wang WL, Lazar AJ, Zhao Z, Prabhakaran S, Bota-Rabassedas N, Futreal A, Patient MOSAIC Team, Yang L, Lin C, Genovese G, Gao J, Wang L, Tannir NM, Msaouel P. Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma. Clin Cancer Res 32(10):1946-1961, 2026. e-Pub 2026. PMID: 42007903.
- Brodsky, AL, Tahan, E, Celestino, J, Tang, X, Raso, G, Meyer-Gauen, S, Bercow, AS, Lawson, BC, Hillman, RT. Expression of antibody drug conjugate target antigens in ovarian sex cord stromal Tumors. Gynecologic oncology 205:99-104, 2026. e-Pub 2026. PMID: 41576550.
- Li J, Takamatsu S, Brodsky AL, Welte T, Calzoncinth K, Vuttaradhi VK, Celestino J, Lawson B, Hillman RT. Tumor-informed liquid biopsy detection of structural variants in high grade serous ovarian cancer. Oncoscience 13:44-54, 2026. e-Pub 2026. PMID: 41835357.
- Zhao J, Mi W, Nair V, Lawson BC, Guo CC, Jacobi EM, Ding Q. B72.3 Serves as a New Diagnostic Marker for Testicular Leydig Cell Tumor. Hum Pathol 168:106026, 2025. e-Pub 2025. PMID: 41443279.
- Ng, CW, Wong, KK, Lawson, BC, Ferri-Borgogno, S, Mok, S. Spatial transcriptome reveals histology-correlated immune signature learnt by deep learning attention mechanism on H&E-stained images for ovarian cancer prognosis. Journal of translational medicine 23(1), 2025. e-Pub 2025. PMID: 39856778.
- Takamatsu, S, Li, J, Welte, T, Khlebus, E, Vuttaradhi, VK, Brodsky, AL, Lawson, BC, Hillman, RT. Long read sequencing reveals novel genomic and epigenomic alterations in repetitive regions of high grade serous ovarian cancer. Scientific reports 15(1), 2025. e-Pub 2025. PMID: 41168225.
- Brodsky, AL, Welte, T, Vuttaradhi, VK, Yang, X, Tahan, E, Khlebus, E, Celestino, J, Powell, RT, Stephan, C, Nguyen, N, Geng, Y, Li, J, Takamatsu, S, Calzoncinth, K, Cobb, LP, Gershenson, DM, Lawson, BC, Hillman, RT. Efficacy of cyclin-dependent kinase 4/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models. Gynecologic oncology 201:152-159, 2025. e-Pub 2025. PMID: 40886461.
- Knisely A, Dai Y, Barlow GL, Lee S, Lawson B, Clark H, Fellman B, Yuan Y, Lu W, Lubo Julio IC, Lazcano RN, Chelvanambi M, Melendez B, Singh B, Singh B, Wani K, Chen J, Yeh CC, Gao J, Barnes S, Shi O, Khan KB, Serrano AG, Gomez-Bolanos LI, Scalise CB, Cheung SK, Dutta P, Velichko S, ElNaggar AC, Liu MC, Wilke RN, How J, Ramondetta LM, Boruta DM, Richardson G, Shafer A, Westin SN, Sims T, Sood AK, Ramirez PT, Lazar AJ, Soliman PT, Lu K, Haymaker CL, Solis Soto LM, Wargo JA, Grisham R, Wucherpfennig KW, Wang L, Jazaeri AA. Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunities. Clin Cancer Res 31(19):4122-4135, 2025. e-Pub 2025. PMID: 40748258.
- Lawson BC, Marques-Piubelli ML, Westin SN, Malpica A. Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases. Int J Gynecol Pathol 44(2):167-173, 2025. e-Pub 2025. PMID: 38914019.
- Welte, T, Vuttaradhi, VK, Khlebus, E, Brodsky, AL, Legarreta, A, Celestino, J, Powell, RT, Stephan, C, Nguyen, N, Li, J, Takamatsu, S, Calzoncinth, K, Sood, AK, Gershenson, DM, Futreal, A, Lawson, BC, Hillman, RT. Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors. Cancer Research 85(5):875-893, 2025. e-Pub 2025. PMID: 39652611.
- Chelariu-Raicu, A, Vu, TC, Umamaheswaran, S, Stur, E, Hanjra, P, Han, Y, Hu, M, Lin, J, Lawson, BC, Liu, J, Sood, AK, Wen, Y. IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer. Cancer Research Communications 5(4):512-526, 2025. e-Pub 2025. PMID: 40029935.
- Li, J, Welte, T, Calzoncinth, K, Vuttaradhi, VK, Brodsky, AL, Wong, KK, Sebastian, MM, Lawson, BC, Kingsley, CV, Hillman, RT. An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor. Gynecologic oncology 194:125-130, 2025. e-Pub 2025. PMID: 40221170.
- Aoun E, Lawson B, Awujo C, Nebgen D, Soletsky BR, Chisholm GB, Lu KH, Nitecki Wilke R. Oncologic outcomes of incidental serous tubal intraepithelial carcinoma and associated high-grade serous carcinoma in high-risk patients undergoing risk-reducing surgery. Int J Gynecol Cancer 36(2), 2025. e-Pub 2025. PMID: 39496390.
- Khlebus EY, Vuttaradhi VK, Ferri-Borgogno S, Brodsky AL, Lawson BC, Mok SC, Hillman RT. Multiplexed Imaging Mass Cytometry Reveals Tumor-immune Microenvironment-dependent Hormone Receptor Expression in Adult-Type Ovarian Granulosa Cell Tumors. Cancer Res Commun 5(10):1894-1909, 2025. e-Pub 2025. PMID: 41042551.
- Negri S, Fisch C, de Hullu JA, van Bommel M, Simons M, Bogaerts J, focus group CS (Lawson,BC), RPMG H, Steenbeek MP. Diagnosis and management of isolated serous tubal intraepithelial carcinoma: A qualitative focus group study. BJOG 131(13):1851-1861, 2024. e-Pub 2024. PMID: 39054407.
- Bowen MB, Melendez B, Zhang Q, Yang RK, Fellman BM, Lawson BC, Adjei NN, Celestino J, Wani KM, Singh B, Urbauer DL, Lazar AJ, Lu KH, Wargo JA, Westin SN, Yates MS. Long-term follow-up of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer reveals relapse characterized by immune exhaustion. Clin Cancer Res 30(22):5073-5082, 2024. e-Pub 2024. PMID: 38922360.
- Cun HT, Bernard L, Lande KT, Lawson BC, Nesbakken AJ, Davidson B, Lindemann K, Fellman B, Sørlie T, Soliman PT, Eriksson AGZ. Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol 189:138-145, 2024. e-Pub 2024. PMID: 39126895.
- Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, Clark N, Hillman RT, Campbell E, Holla V, Johnson AM, Biter AB, Yuan Y, Cobb LP, Gershenson DM, Jazaeri AA, Lu KH, Soliman PT, Westin SN, Euscher ED, Lawson BC, Yang RK, Meric-Bernstam F, Hong DS. Clinical and genomic landscape of RAS mutations in gynecologic cancers. Clin Cancer Res 30(14):2986-2995, 2024. e-Pub 2024. PMID: 38687597.
- How JA, Legarreta AF, Handley KF, Fellman B, Foster KI, Glassman D, Vuttaradhi VK, Brodsky AL, Lawson BC, Frumovitz M, Westin SN, Ramondetta LM, Gershenson DM, Sood AK, Hillman RT. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol 230(5):544.e1-544.e13, 2024. e-Pub 2024. PMID: 38191019.
- Chien YW, Wang Y, Huang P, Lawson BC, Kolin DL, Chui MH, Vang R, Numan TA, Soong TR, Wang BG, Smith SA, Chen CL, Stone R, Douville C, Wang TL, Shih IM. Morphologic and Molecular Heterogeneity of High-grade Serous Carcinoma Precursor Lesions. Am J Surg Pathol 48(4):475-486, 2024. e-Pub 2024. PMID: 38298022.
- Ferri-Borgogno S, Burks JK, Seeley EH, McKee TD, Stolley DL, Basi AV, Gomez JA, Gamal BT, Ayyadhury S, Lawson BC, Yates MS, Birrer MJ, Lu KH, Mok SC. Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics Analyses. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473208.
- Liu Y, Lawson BC, Huang X, Broom BM, Weinstein JN. Prediction of Ovarian Cancer Response to Therapy Based on Deep Learning Analysis of Histopathology Images. Cancers (Basel) 15(16), 2023. e-Pub 2023. PMID: 37627071.
- Euscher ED, Marques-Piubelli ML, Ramalingam P, Wistuba I, Lawson BC, Frumovitz M, Malpica A. Extrauterine Mesonephric-like Carcinoma: A Comprehensive Single Institution Study of 33 Cases. Am J Surg Pathol 47(6):635-648, 2023. e-Pub 2023. PMID: 37026792.
- Foster KI, Flores Legarreta A, Kamat R, Handley KF, Glassman D, How JA, Lawson BC, Westin SN, Ramondetta LM, Frumovitz M, Gershenson DM, Sood AK, Hillman RT. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol 228(6):724.e1-724.e9, 2023. e-Pub 2023. PMID: 36907533.
- Khlebus E, Vuttaradhi VK, Welte T, Khurana N, Celestino J, Beird HC, Gumbs C, Little L, Legarreta AF, Fellman BM, Nguyen T, Lawson BC, Ferri-Borgogno S, Mok SC, Broaddus RR, Gershenson DM, Futreal PA, Hillman RT. Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors. Mol Cancer Res 21(5):OF1-OF12, 2023. e-Pub 2023. PMID: 37068116.
- Zhang X, Yao J, Niu N, Li X, Liu Y, Huo L, Euscher ED, Wang H, Bell D, Sood AK, Wang G, Lawson BC, Ramalingam P, Malpica A, Sahin AA, Ding Q, Liu J. SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. Mod Pathol 36(2), 2023. e-Pub 2023. PMID: 36853778.
- Silva EG, Lawson BC, Ramalingam P, Liu J, Shehabeldin A, Marques-Piubelli ML, Malpica A. Precursors in the ovarian stroma: another pathway to explain the origin of ovarian serous neoplasms. Hum Pathol 127:136-145, 2022. e-Pub 2022. PMID: 35427637.
- Zhang L, Au-Yeung CL, Huang C, Yeung TL, Ferri-Borgogno S, Lawson BC, Kwan SY, Yin Z, Wong ST, Thomas V, Lu KH, Yip KP, Sham JSK, Mok SC. Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes. J Exp Clin Cancer Res 41(1):242, 2022. e-Pub 2022. PMID: 35953818.
- Hillman RT, Lin DI, Lawson BC, Gershenson DM. Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. Gynecol Oncol 162(3):728-734, 2021. e-Pub 2021. PMID: 34238613.
- Lawson BC, Yang RK, Euscher ED, Ramalingam P, Malpica A. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma. Hum Pathol 115:76-83, 2021. e-Pub 2021. PMID: 34153306.
- Chen PP, Ramalingam P, Alvarado-Cabrero I, Euscher ED, Nagarajan P, Lawson BC, Malpica A. High-grade Neuroendocrine Carcinomas of the Vulva: A Clinicopathologic Study of 16 Cases. Am J Surg Pathol 45(3):304-316, 2021. e-Pub 2021. PMID: 32826525.
- Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel) 13(4):1-14, 2021. e-Pub 2021. PMID: 33572451.
- Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?. Am J Surg Pathol 44(2):206-213, 2020. e-Pub 2020. PMID: 31651523.
- Shen W, Niu N, Lawson BC, Qi L, Zhang J, Li T, Zhang H, Liu J. GATA6: a new predictor for prognosis in ovarian cancer. Hum Pathol 86:163-169, 2019. e-Pub 2019. PMID: 30633927.
Review Articles
- How, JA, Jazaeri, AA, Westin, SN, Lawson, BC, Klopp, AH, Soliman, PT, Lu, KH. Translating biological insights into improved management of endometrial cancer. Nature Reviews Clinical Oncology 21(11):781-800, 2024. e-Pub 2024. PMID: 39198622.
Other Articles
- Liu Y, Lawson BC, Huang X, Broom BM, Weinstein JN RETRACTED: Liu et al. Prediction of Ovarian Cancer Response to Therapy Based on Deep Learning Analysis of Histopathology Images. Cancers 2023, 15, 4044. Cancers (Basel) 16(3), 2024. PMID: 38339431.
- Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH Transforming Ovarian Cancer Care by Targeting Minimal Residual Disease. Med 4(11):755-760, 2023. PMID: 37951209.
Abstracts
- Fleming, N, Wolfe, CA, Keating, MF, Sans, M, Rangel, KM, Sunny, C, Westin, SN, Jazaeri, AA, Soliman, PT, Taylor, JS, Hillman, RT, How, JA, Lawson, BC, Sood, AK, Eberlin, LS. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery. Journal of Clinical Oncology 42:5573, 2024. e-Pub 2024.
- Fleming N, Wolfe C, Keating M, Sans M, Rangel K, Sunny C, Westin S, Jazaeri A, Soliman P, Taylor J, Hillman R, How J, Lawson BC, Sood A, Eberlin L. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery. Clin Oncol 42(16), 2024. e-Pub 2024.
- Dai Y, Knisely A, Lawson BC, Lee S, Wani K, Segura R, Melendez B, Chen J, Liu Y, Chelvanambi M, Gibson L, Johnson S, Yeh C, Ingram D, Hudgens C, k C, Pei G, Jiang J, Chu Y, Lazar A, Gao J, Wargo J, Wang L, Jazaeri A. Longitudinal spatial profiling reveals chemoresistance mechanisms and characteristics of minimal residual disease in high-grade serous ovarian cancer. Cancer Research 84(6), 2024. e-Pub 2024.
- Vuttaradhi V, Khlebus E, Welte T, Lawson BC, Hillman R. Oncogenic Foxl2 directs enhancer reprogramming and changes in 3D genome structure in ovarian granulosa cell tumors. Cancer Research 84(5), 2024. e-Pub 2024.
- Li J, Takamatsu S, Little L, Celestino J, Lawson BC, Hillman R. Liquid biopsy detection of structural variant breakpoints to monitor ovarian cancer clonal evolution. Clin Oncol 42, 2024. e-Pub 2024.
- Euscher E, Marques-Piubelli M, Lawson BC, Malpica A, Ramalingam P. 4 MLH1 Hypermethylated Endometrial Carcinomas Have Similar Outcomes to NonMLH1 Hypermethylated Tumors. Mod Pathol 104(3):S1141-43, 2024. e-Pub 2024.
- Chien Y, Wang Y, Lawson BC, Kolin D, Chui M, Vang R, Numan T, Soong T, Wang B, Smith S, Chen C, Douville C, Huang P, Wang T, Shih L. Morphological and Molecular Heterogeneity of Serous Tubal Intraepithelial Carcinomas. Mod Pathol 104(3):S1125-26, 2024. e-Pub 2024.
- Cuna H, Bernarda L, Lande K, Lawson BC, Davidson B, Sorlie T, Lindemann K, Fellman B, Soliman P, Eriksson A. Comprehensive molecular characterization of deeply invasive, node negative grade 3 endometrioid adenocarcinoma (2285). Gynecologic Oncology 176(1):S307, 2023. e-Pub 2023.
- Son J, Turner B, Lawson BC, Sun C, Hong D, Curran M. Changes in “don't eat me” signaling with radiotherapy in endometrial cancer (2301). Gynecologic Oncology 176(1):S316, 2023. e-Pub 2023.
- How J, Legarreta A, Fellman B, Handley K, Foster K, Glassman D, Lawson BC, Ramondetta L, Gershenson D, Sood A, Hillman R. Impact of cytoreductive surgery on survival outcomes for recurrent adult-type granulosa cell tumors of the ovary. Clin Oncol 41(16), 2023. e-Pub 2023.
- Welte T, Vuttaradhi V, Khlebus E, Lawson BC, Hillman T, Nguyen N, Sobieski M, Powel R, Stephan C. Targeting FOXL2C402Gvulnerabilities in adult type ovarian granulosa cell tumors. Cancer Research 83(7), 2023. e-Pub 2023.
- Khlebus E, Vuttaradhi V, Welte T, Khurana N, Celestino J, Beird H, Gumbs C, Little L, Legarreta A, Nguyen T, Lawson BC, Broaddus R, Gershenson D, Futreal A, Hillman T. Tumor microenvironment composition correlates with relapse in ovarian granulosa cell tumors. Cancer Research 83(7), 2023. e-Pub 2023.
- Vuttaradhi V, Khlebus E, Welte T, Khurana N, Lawson BC, Hillman R. Oncogenic Foxl2 is a chromatin-remodeling pioneer transcription factor in adult-type ovarian granulosa cell tumors. Cancer Research 83(7), 2023. e-Pub 2023.
- Rahbar Z, George S, Lawson BC, Torres- Cabala CA, Curry JL, Aung PP, Ivan D, Prieto VG, Nagarajan P. Acantholytic dermatosis of the genitocrural region, 2023. e-Pub 2023.
- Wang G, Liu Y, Malpica A, Eushcer E, Lawson BC, Hameed N, Sood A, Rafei H, Basar R, Rezvani K, Jazaeri A, Liu J. TROP2 Expression is A Favorable Prognostic Marker in Patients with Advanced High Grade Ovarian Carcinoma. Mod Pathol 103(3):S998-S99, 2023. e-Pub 2023.
- Lawson BC, Malpica A. Borderline and Malignant Brenner Tumors: A Clinicopathologic Study of 43 Cases. Mod Pathol 103(3):S937-S938, 2023. e-Pub 2023.
- Handley K, Glassman D, Legarreta A, Frumovitz M, Lawson BC, Gershenson D, Sood A, Ramondetta L, Hillman R. Tumor reductive surgery and survival outcomes in recurrent adult type granulosa cell tumors of the ovary (152). Gynecologic Oncology 166(1):S92, 2022. e-Pub 2022.
- Zhang Y, Handley K, Glassman D, Legarreta A, Frumovitz M, Lawson BC, Gershenson D, Sood A, Ramondetta L, Hillman R. Anatomic patterns of recurrence in adult type granulosa cell tumors of the ovary (161). Gynecologic Oncology 166(1):S96, 2022. e-Pub 2022.
- Euscher E, Ramlingam P, Lawson BC, Malpica A. Extra-Uterine Mesonephric-Like Carcinoma: A Single Institution Clinicopathologic Study of 21 Cases. Mod Pathol 35(2), 2022. e-Pub 2022. PMID: 35302092.
- Hameed N, Euscher E, Ramalingam P, Marques-Piubelli M, Lawson BC, Malpica A. Reporting Lymph Node Metastasis Size and Extracapsular Extension for Ovarian, Fallopian Tube and Peritoneal Carcinoma Is Not Clinically Relevant. Mod Pathol 35(2), 2022. e-Pub 2022. PMID: 35302092.
- Cox H, Euscher E, Ramalingam P, Marques-Piubelli M, Lawson BC, Malpica A. Clear Cell Carcinoma of the Cervix, A Clinicopathologic Study of 33 Cases in the Post-Diethylstilbestrol (DES) Era. Mod Pathol 35(2), 2022. e-Pub 2022. PMID: 35302092.
- Euscher E, Marques-Piubelli M, Ramlingam P, Lawson BC, Malpica A. Extra-Uterine Mesonephric-Like Carcinoma Is Associated with Endometriosis and May Behave Aggressively. Mod Pathol 35(2), 2022. e-Pub 2022. PMID: 35302092.
- Wang G, Lawson BC, Euscher E, Ramalingam P, Malpica A, Yang R. Patients with Stage III-IV ARID1A Mutated Gynecologic Carcinomas Have Better Overall Survival when Treated with Immune Checkpoint Blockade Therapy. Mod Pathol 35(2), 2022. e-Pub 2022. PMID: 35302092.
- Griffin B, Malpica A, Lawson BC. Evaluation of Her-2neu Expression in Gynecological Cancers: An Oncologic Institutional Experience. Mod Pathol 34(2):688-689, 2021. e-Pub 2021.
- Abdul Karim L, Yang R, Ramalingam P, Lawson BC, Malpica A. Correlation of p53 Immunohistochemical Expression in Extrauterine High-Grade Serous Carcinoma. Mod Pathol 34(2):639-640, 2021. e-Pub 2021.
- Euscher E, Ramalingam P, Marques-Piubelli M, Lawson BC, Rashid A, Malpica A. Comparison of KRAS-Mutated Mesopnephric-Like and Non Mesonephric-Like Carcinomaj of the Endometrium. Mod Pathol 34(2):677-678, 2021. e-Pub 2021.
- Ramalingam P, Yang R, Lawson BC, Euscher E, Malpica A. Next generation Sequencing in Peritoneal versus Pleural Mesotheliomas-Commonalities and Differences. Mod Pathol 33(2):1119-1120, 2020. e-Pub 2020.
- Lawson BC, Yang R, Euscher E, Ramalingam P, Malpica A. Chemotherapy Response Score in Extrauterine High Grade Serous Carcinoma and Association with Mutation Status by Next-Gen Sequencing. Mod Pathol 33(2):1092-1093, 2020. e-Pub 2020.
- Chen P, Euscher E, Ramalingam P, Lawson BC, Malpica A. High-Grade Neuroendocrine Carcinoma of the Vulva: A Clinicopathologic Study of 15 Cases. Mod Pathol 33(2):1028-1029, 2020. e-Pub 2020.
- Lawson BC, Euscher E, Bassett R, Liu J, Ramalingam P, Zhong Y, Fleming N, Malpica A. A 3 Tier Chemotherapy Response Score For Ovarian/Fallopian Tube/Peritoneal High Grade Serous Carcinoma, Is It Clinically Relevant?. Mod Pathol 32(2):67-38, 2019. e-Pub 2019.
- Lawson BC, Malpica A, Gruschkus S, Bassett R, Euscher E. Circumferential Horizontal Extent in Microscopic Invasive Cervical Cancer, Is It Relevant?. Mod Pathol 32(2):66-67, 2019. e-Pub 2019.
- Zhong Y, Lawson BC, Malpica A, Euscher E, Ramalingam P, Fleming N, Sood A, Liu J. Histological Features not Inlcuded in the Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High Grade Serous Carcinoma, Are They Relevant?. Mod Pathol 32(2):137-138, 2019. e-Pub 2019.
- Lawson BC. Clinical Behavior and Gene Expression in Borderline and Malignant Brenner Tumors. Virchows Archiv.
- Wolf C, Lawson BC. Using the MSPen Technology for Intraoperative Identification of High-Grade Serous Carcinoma Metastatic Sites During Ovarian Cancer Surgeries. Journal of the American Society for Mass Spectrometry.
- Jing Han, Patricia Repollet Otero, William Mi, Nadia Hameed, Elizabeth Euscher, Lawson B. 982 Interobserver Reproducibility of Folate Receptor Alpha (FOLR1) Scoring in High-Grade Serous Carcinoma. USCAP 106(3).
Book Chapters
- Lawson BC. 10.5 Ovarian Sex Cord- Stromal Tumors: Pathology and Prognostic Factors. In: Principles and Practice of Gynecologic Oncology. 8th. Wolters Kluwer, 2024.
- Hinchcliff, EM, Lawson, BC, Fleming, N. Chapter 10 Other rare uterine sarcomas. In: Diagnosis and Treatment of Rare Gynecologic Cancers. Elvsevier, 161-182, 2023.
- Hinchcliff, EM, Lawson, BC, Ratan, R, Soliman, PT. Chapter 9 Uterine leiomyosarcoma. In: Diagnosis and Treatment of Rare Gynecologic Cancers. Elsevier, 145-160, 2023.
- Cantrell, LA, Lawson, BC, Peng, K. Chapter 11 Uterine carcinosarcoma. In: Diagnosis and Treatment of Rare Gynecologic Cancers. Elsevier, 183-196, 2023.
- Knisely, A, Lawson, BC, Wright, JD. Chapter 13 Other rare uterine cancers. In: Diagnosis and Treatment of Rare Gynecologic Cancers. Elsevier, 213-231, 2023.
- Broach, V, Lawson, BC. Chapter 18 Bartholin gland carcinomas. In: Diagnosis and Treatment of Rare Gynecologic Cancers. Elsevier, 305-314, 2023.
- Kurnit, KC, Lawson, BC, Yamada, SD, Herbst, A. Chapter 16 Clear cell carcinoma of the vagina and cervix. In: Diagnosis and Treatment of Rare Gynecologic Cancers. Elsevier, 265-276, 2023.
Patient Reviews
CV information above last modified September 16, 2026